Abstract:Whole embryo culture appears to be an excellent method to screen chemicals for teratogenic hazard. Compared to in vivo testing it is cheap and rapid and does not involve experimentation on live adult animals. Also in the important area of risk estimation whole embryo culture offers distinct advantages over in vivo teratogenicity testing. Adverse embryonic outcomes (malformations or embryotoxicity) are directly related to the serum concentration of the compound being tested and can be compared to the serum concentration in the human. A similar comparison is not possible after in vivo testing because for most compounds there are major pharmacokinetic differences between humans and experimental animals. In vivo testing is also limited by the possibility that metabolites that occur in the human do not occur in the test animal. This problem can be overcome in the in vitro system by adding the metabolite directly at the desired concentration either with or without the parent compound. There is only one major disadvantage to in vitro testing and that is the limited period of embryogenesis that is undertaken in the commonly used culture system. This restricts the range of malformations that can be induced and may render the testing system unsuitable for compounds that are likely to exert their major toxicological effect late in gestation. Any evaluation of whole embryo culture for hazard and risk assessment in teratology must take into account the limited value of currently used in vivo methods. Over 2000 chemicals have been reported to be teratogenic in experimental animals exposed in vivo (Shepard, Catalog of Teratogenic Agents, 1989). In comparison only about 20 chemicals are known to cause birth defects in the human. This large number of in vivo false-positive cannot easily be distinguished from true-positives. In this respect in vivo testing is severely deficient. The embryo culture testing system would also be expected to produce many false-positives; but by comparing effective drug concentrations with human therapeutic concentrations they can be differentiated from true-positives. The most serious deficiency for an in vivo or in vitro teratogenicity testing system would be false-negatives. This has not been a problem in the validation of in vitro testing so far (except perhaps procarbazine), but difficult drugs such as thalidomide were not included. Thalidomide remains an important index chemical because it is not teratogenic in rats or mice but is teratogenic in the rabbit and human. It is likely that these species differences are due to metabolic differences between species and it is possible that if the proximate teratogen/s of thalidomide were identified they would be teratogenic in rat embryo culture. Whole embryo culture remains a very powerful technique that should continue to contribute to the determination of the safety of drugs and other chemicals during pregnancy.

The Embryonic Stem Cell Test as Tool to Assess Structure-Dependent Teratogenicity: The Case of Valproic Acid

Assaying embryotoxicity in the test tube: Current limitations of the embryonic stem cell test (EST) challenging its applicability domain

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

An automated and high-throughput-screening compatible pluripotent stem cell-based test platform for developmental and reproductive toxicity assessment of small molecule compounds

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Embryotoxicity estimation of commonly used compounds with embryonic stem cell test

A Modified Murine Embryonic Stem Cell Test for Evaluating the Teratogenic Effects of Drugs on Early Embryogenesis

Valproic acid teratogenicity: a toxicogenomics approach

Embryotoxicity assessment of developmental neurotoxicants using a neuronal endpoint in the embryonic stem cell test

The Human Induced Pluripotent Stem Cell Test as an Alternative Method for Embryotoxicity Testing

Assessment of embryotoxicity of compounds in cosmetics by the embryonic stem cell test

Expression of Sox-2 in mouse embryonic stem cell test for screening drugs with embryotoxicity

Animal-free assessment of developmental toxicity: Combining PBPK modeling with the ReproTracker assay

Tissue-specific effects of valproic acid on DNA repair genes and apoptosis in postimplantation mouse embryos

Assessment of the Developmental Toxicity of Epidermal Growth Factor Using Embryonic Stem Cell Test

Comparison of Embryotoxicity of Di(2-Ethylhexyl) Phthalate Using Mouse and Human Embryonic Stem Cell Test Models in Vitro

Investigating the applicability domain of the hiPSC-based PluriLum assay: an embryotoxicity assessment of chemicals and drugs

A review of the contribution of whole embryo culture to the determination of hazard and risk in teratogenicity testing

Optimization of the TeraTox assay for preclinical teratogenicity assessment

The proteomic and genomic teratogenicity elicited by valproic acid is preventable with resveratrol and α-tocopherol

Transcriptome-based prediction of drugs, inhibiting cardiomyogenesis in human induced pluripotent stem cells